We Are DA32

Life Science Tech

We are living in the century of biology, an incredibly dynamic period of innovation, where biologic insights and rapid advances in technology and data analytics are colliding to create an unprecedented positive impact on human health.

our competitive edge


Spanning all aspects of life sciences technology

Deep Industry

Across the life sciences technology ecosystem

Proven Company

Bringing our combined strategic, operational and financing experiences

Successful Track Record of Innovation Investing

At all stages of development (public and private companies)

We Are

DA32 Life Science Tech is a Special Purpose Acquisition Corp (SPAC) dedicated to funding, building and catalyzing the most promising opportunities in life science tech.

Leveraging the complimentary capabilities of our founding sponsors Deerfield, ARCH Venture Partners and Section 32, our mission is to deliver investor returns while making a positive impact on human health and humanity.


Taken together, our Co-Sponsors, Directors, and Strategic Advisors bring a unique and unmatched combination of scientific expertise, accomplished investing, operational and company-building experience and extensive industry relationships to help guide private and public companies in delivering tangible improvements in health outcomes for individuals and society.

Executive Team
And Directors

Steve Kafka, Ph.D.
Chief Executive Officer and Director
Andrew ElBardissi, M.D.
Keith Crandell
Chris Wolfe
Chief Financial Officer

Board Members
Independent Directors

Mara Aspinall

Managing Director, BlueStone Venture Partners;
Former President and CEO, Ventana Medical Systems

Kevin Hrusovsky

President, Chairman and CEO Quanterix;
Former President of Life Sciences and Technologies, PerkinElmer

Angela Lai

CEO and Founder, BetterOmics;
Former Chief Technology Officer, Grail

Nick Roelofs, Ph.D.

Advising Partner, Summa Equity;
Former President, Life Sciences Group, Agilent


Bonnie Anderson

Co-founder, Executive Chairwoman, and
Former CEO, Veracyte

Peer Schatz

Managing Director, PS Capital Management GmbH;
Former CEO, Qiagen

Vince Miller, M.D.

Physician-in-Chief, EQRx; Former Chief Medical Officer,
Foundation Medicine; Thoracic Oncology Physician,
Memorial Sloan Kettering Cancer Center

Mike Pellini, M.D.

Managing Partner, Section 32;
Former Chairman and CEO, Foundation Medicine


The life sciences market is experiencing rapid growth, creating a substantial market opportunity for life sciences technology companies. We believe the time is ripe for innovation and disruption by novel technologies in key areas including:


Scientific advances in diagnostics are driving-down costs and driving-up utility and ultimately delivering on the promise of better, more personalized care

  • Diagnostic instrument providers
  • Laboratory services platforms
  • Expanding areas of application

Data and analytics platforms

Digitization of data, machine learning and AI, and mobile computing are converging in new and meaningful ways for patients, providers and payers to enable better decision making and enhanced care delivery

  • Data and machine learning software
  • Mobile technologies
  • Improvements in research, drug development, and clinical care

Life Sciences

Breakthroughs in biology, genomics and proteomics, automation, digitization, optics and other technologies are revolutionizing how we discover, develop and deliver patient care

  • Analytical instrumentation platforms
  • Outsourced drug discovery and development platforms


Improved engineering and the manipulation of natural biological processes are transforming the speed and efficiency of developing new therapies, diagnostics and industrial solutions

  • Platform companies
  • Genes, libraries, and oligo pools
  • DNA-based data storage


  • Large and growing markets ripe for disruption by novel technologies
  • New frontiers that will be created by scientific and technological innovation
  • Value creation for all participants in life science tech: patients, providers, payers, researchers, clinicians, investors


  • Unique combination of operational expertise and capital support across all stages of development – private and public companies
  • Management and company-building support
  • Integration of lessons learned to drive significant value creation

In the


SEC Filings: Easily access DA32 filings with SEC


DA32 Life Science Tech Acquisition Corp., Sponsored by Deerfield, ARCH Venture Partners and Section 32, Announces Closing of $200 Million Initial Public Offering


Contact Us

We're happy to hear from you.
Please reach out to us.

Steve Kafka, Ph.D.

Chief Executive Officer and Director

Steve is a managing partner of Section 32, where he focuses on innovation at the confluence of life sciences and technology. Steve has led the Section 32’s’ investments in companies including Thrive Earlier Detection, Glympse Bio, Celsius Therapeutics, C2i Genomics, ImmuneID and ROME Therapeutics.

Steve is an accomplished company-builder and strategic leader in molecular diagnostics and data: Steve was founding CEO and executive chairman of Thrive, acquired by Exact Sciences in January 2021; he was executive chairman of ArcherDx, acquired by Invitae Corporation in October 2020; and, Steve was President and CEO of Foundation Medicine, acquired by Roche in June 2018.

Steve holds a Ph.D. in political economy and government from Harvard University and an A.B. degree in economics and political science from Stanford University.

Andrew ElBardissi, M.D.


Dr. ElBardissi is a partner on the structured products team at Deerfield and focuses on life sciences and healthcare technology including diagnostics and life sciences tools.

At Deerfield, Dr. ElBardissi has led investments and serves or served on the Boards of Sema4, Singular Genomics, Encodia, DNAMx, Epic Sciences, Acutus, Farapulse Endologix, Element Science, and InCarda Therapeutics, among others.

Previously, Dr. ElBardissi was a Principal at Longitude Capital and a banker in J.P. Morgan’s healthcare practice.

Dr. ElBardissi holds an M.D. from Mayo Clinic, MBA from Harvard Business School, MPH from Harvard University and B.S. from Pennsylvania State University. He received clinical research training at the Harvard School of Public Health and residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University.

Keith Crandell


Mr. Crandell is a co-founder and has served as a Managing Director of ARCH Venture Partners since July 1994, where he focuses on life sciences tools, devices, and diagnostics.

He currently serves on the board of directors of Quanterix Corporation, a publicly-traded company focusing on ultra-sensitive digital biomarker detection, Twist Bioscience, a publicly-traded syn bio company whose silicon-based DNA writing platform offers broad application across the life sciences and biotheraputics, and 908 Devices a publicly-traded company focused on bringing mass spectrometry to bio discovery and processing and field forensic applications.

Mr. Crandell has played a key role in the formation and initial funding round of life sciences companies including Quanterix (QTRX), Twist Biosciences (TWST), and 908 Devices (MASS) among others.

Mr. Crandell is also a director of several private companies and serves on the Entrepreneurship Advisory Board at the Polsky Center for Entrepreneurship, the University of Chicago Booth School of Business, the University of Chicago Pritzker School of Molecular Engineering Advisory Council, and on the investment advisory board for the Partners Innovation Fund, a venture capital fund affiliated with Harvard Medical School Hospitals.

Mr. Crandell has a B.S. degree in chemistry and mathematics from St. Lawrence University, an M.S. in chemistry from the University of Texas at Arlington, and an M.B.A. from the University of Chicago.

Chris Wolfe

Chief Financial Officer​

Mr. Wolfe has 20 years of experience in investing in healthcare and services businesses with a focus on complex and structured transactions.

He has served as Chief Financial Officer of the Deerfield-sponsored SPACs, including DFB Healthcare Acquisitions Corp, DFP Healthcare Acquisitions Corp, and Deerfield Healthcare Technology Acquisitions Corp.

He helped source, negotiate, structure, and execute the business combination transactions with AdaptHealth Corp. and CareMax Inc.

Prior to that, he was a partner of Capital Z Partners, a middle-market private equity fund that has invested $3 billion in over 50 transactions since 1990, and worked in M&A at Credit Suisse First Boston.

Mr. Wolfe graduated magna cum laude from Harvard College.